Assistant Professor, Therapeutic Radiology, Yale University School of Medicine
Radiation Oncology
Dr. Roy H. Decker, MD
|
|
Give Review
Doctor Roy H. Decker, MD works in the field of Radiation Oncology. He graduated from Virginia Commonwealth University School of Medicine. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Roy H. Decker, MD is a published doctor. He has 55 papers published. The most current publication "Comparison of laparoscopic and open staging in Hodgkin disease." He is registered with Medicare.
Publications
- Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
- Taking "the Game" Out of The Match: A Simple Proposal.
- Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation.
- Central vs. peripheral tumor location: influence on survival, local control, and toxicity following stereotactic body radiotherapy for primary non-small cell lung cancer.
- Bolstering the case for lobectomy in stage I, II and IIIA small cell lung cancer using the National Cancer Data Base.
- Re-evaluation of the role of post-operative radiotherapy and the impact of radiation dose for non-small cell lung cancer using the National Cancer Database.
- Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States.
- Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base.
- A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer.
- ACR Appropriateness Criteria Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent.
- Impact of preoperative radiation on survival of patients with T3N0 >7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiolo...
- ACR Appropriateness Criteria® Radiation Therapy for Small-Cell Lung Cancer.
- Pulmonary resections following prior definitive chemoradiation therapy are associated with acceptable survival.
- Use of new treatment modalities for non-small cell lung cancer care in the Medicare population.
- Stereotactic Body Radiotherapy for Central Lung Tumors.
- Characteristics Associated With the Use of Nonanatomic Resections Among Medicare Patients Undergoing Resections of Early-Stage Lung Cancer.
- Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer.
- Evaluation and treatment of high-risk patients with early-stage lung cancer.
- ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung cancer.
- The Prognostic Importance of Midline Involvement in Oral Tongue Cancer.
- The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
- Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy.
- Surveillance, Epidemiology, and End Results (SEER) database analysis of microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) of the skin.
- Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer.
- A prognostic index for predicting lymph node metastasis in minor salivary gland cancer.
- Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
- Impact of immediate postoperative death on the estimation of a survival benefit from postoperative radiation therapy for cancer of the gallbladder.
- Advances in radiotherapy for lung cancer.
- Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database.
- Postoperative radiation therapy for non-small cell lung cancer.
- The role of postoperative radiation therapy (PORT) in the treatment of extrahepatic bile duct cancer: a surveillance, epidemiology, and end results (SEER) population-b...
- Regarding adjuvant radiation therapy in merkel cell carcinoma: selection bias and its affect on overall survival.
- Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005.
- Role of radiotherapy in the management of merkel cell carcinoma of the skin.
- Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities.
- Evaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy.
- Nutritional support of patients undergoing radiation therapy for head and neck cancer.
- Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.
- A significant decrease in rectal volume and diameter during prostate IMRT.
- Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma.
- Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis.
- Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells.
- Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
- The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosi...
- The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.
- Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and ...
- Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mito...
- ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung.
- The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers.
- ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent.
- A 71-year-old woman with myelofibrosis, hypoxemia, and pulmonary hypertension.
- Disclosing medical errors: a practical guide and discussion of radiation oncology-specific controversies.
- Comparison of laparoscopic and open staging in Hodgkin disease.
- Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
Schools
Virginia Commonwealth University Medical College Of Virginia School Of Medicine
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Yale-New Haven Hospital -
Virginia Commonwealth University Health System -
Virginia Commonwealth University School of Medicine
Hospital
-
Greenwich Hospital -
Yale-New Haven Hospital
Drug Facts
| NPI NUMBER | 1477673564 | |
| NPPES Provider LastName | DECKER | |
| NPPES Provider FirstName | ROY | |
| NPPES Provider ZIPCode | 065208040 | |
| NPPES Provider State | CT | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 82.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477673564 |
| Last Name Of The Provider | DECKER |
| First Name Of The Provider | ROY |
| View All |
Similar Doctors
|
|
Dr. Joyce Y. Chung, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter M. Glazer, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. James B. Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arie P. Dosoretz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam J. Kole, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nadine Housri, MD |
|
|
Dr. Steven C. Oh, MD |